Emergent BioSolutions to team its Ebola vaccine with GSK's in Phase I
This article was originally published in Scrip
Executive Summary
Emergent BioSolutions has completed the manufacture of the first clinical lot of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) that will be used in a Phase I trial together with GlaxoSmithKline's Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate as a heterologous boost. The Phase I study will be conducted in the UK at the Jenner Institute in Oxford, supported by a grant from the Wellcome Trust and the UK Department for International Development. Under several agreements that it signed with the University of Oxford, GSK, and the US National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID), Emergent has performed proof of concept work and manufactured the MVA EBOZ vaccine candidate at a 200L scale in an avian cell line. Manufacturing in this cell line has significant advantages including removing the requirement for eggs from the manufacturing process, consistency of manufactured vaccine lots, and increases in doses delivered, the company said. The scalable process has the potential to meet the demand for multi-million doses in a few months.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.